In this pharmaceutical executive video interview, Panna Sharma, CEO of Lantern Pharma, explains what specific endpoints the Phase I trial will focus on to evaluate the potential efficacy of LP-284 and what results will be obtained. How insights are fed back into RADR®.
Evaluation of LP-284 using RADR for NHL and other targeted cancers
Leave a Comment
